Markers to Determine Arrhythmia Vulnerability in End Stage Heart Failure.

Markers to Determine Arrhythmia Vulnerability in End Stage Heart Failure. - Arrhythmia vulnerability in heart failure, AVES-HF

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39922

Enrollment

Registered

2012-03-12

Start date

2013-01-15

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arrhythmia heart failure reduced heart function

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients will be included if they are over 18 years and under 80 years and able to give informed consent. Patients with end stage heart failure undergoing LVAD implantation.

Exclusion criteria

Exclusion criteria: Under 18 and over 80 years The inclusion criteria includes only the study population.

Design outcomes

Primary

Measure	Time frame
Measurements of the electrophysiological, structural and (immuno) histological characteristics of mature ventricular cardiomyocytes and serum markers.	—

Secondary

Measure	Time frame
Potential electrical markers and biomarkers for arrhythmia vulnerability.	—

Countries

Netherlands

Outcome results